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Nogo-A Downregulation Improves Insulin Secretion
in Mice
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Type 2 diabetes (T2D) is characterized by b-cell dysfunction and
the subsequent depletion of insulin production, usually in a con-
text of increased peripheral insulin resistance. T2D patients are
routinely treated with oral antidiabetic agents such as sulfonylur-
eas or dipeptidyl peptidase-4 antagonists, which promote glucose-
and incretin-dependent insulin secretion, respectively. Interestingly,
insulin secretion may also be induced by neural stimulation. Here
we report the expression of Nogo-A in b-cells. Nogo-A is a mem-
brane protein that inhibits neurite outgrowth and cell migration in
the central nervous system. We observed that Nogo-A–deficient
mice display improved insulin secretion and glucose clearance. This
was associated with a stronger parasympathetic input and higher
sensitivity of b-cells to the cholinergic analog carbachol. Insulin
secretion was also improved in diabetic db/db mice treated with
neutralizing antibody against Nogo-A. Together, these findings sug-
gest that promoting the vagal stimulation of insulin secretion
through the selective inhibition of Nogo-A could be a novel thera-
peutic approach in T2D. Diabetes 62:1443–1452, 2013
The relative or absolute lack of insulin is re-sponsible for diabetes. In type 1 diabetes, b-cellloss is due in most cases to an autoimmune re-action, but not exclusively (1). In type 2 diabetes
(T2D), increased peripheral insulin resistance challenges
the functional b-cell mass; after an initial attempt at
overriding the increased insulin demand, the number of
cells that produce insulin declines progressively.
Glucose entry into cells is regulated by insulin, whose
secretion from b-cells is tightly coordinated by different
secretagogues. Insulin secretion is initiated by the cholin-
ergic parasympathetic stimulation of b-cells (the so-called
“cephalic phase”) and subsequently potentiated during the
enteric “absorptive phase” (2). In response to mechanical
and chemical stimulation along the digestive tract, the in-
testinal incretin hormones glucagon-like peptide-1 (GLP-1)
and gastric inhibitory peptide (GIP) potentiate insulin se-
cretion directly and indirectly, through neuronal stimula-
tion (the “incretin effect”) (3–5). Progressively, nutrient
absorption and increased blood glucose stimulate insulin
secretion directly (post-absorptive phase) (6). Altogether,
different secretagogues act synergistically and trigger the
adequate biphasic release of insulin from b-cells, primed
by cholinergic stimulation (7). These secretagogues reach
islet endocrine cells through the vascular and neural net-
works. Pancreas innervation consists of parasympathetic
(vagus nerve) and sympathetic efferent fibers and afferent
sensory fibers (splanchnic nerve), and of intrapancreatic
parasympathetic ganglion cells. The vagal input stimulates
the secretion of insulin and other islet hormones, such as
pancreatic polypeptide (PP) via cholinergic (i.e., mediated
by acetylcholine) and noncholinergic mechanisms (8–10).
Sympathetic postganglionic terminal nerves release nor-
adrenaline or other peptides on endocrine cells; this
represses insulin and somatostatin secretion while pro-
moting glucagon release (11). The afferent sensory fibers
innervate the periphery of islets and release calcitonin
gene-related peptide (CGRP), among other peptides
(12,13).
b-Cells and neurons share numerous features. They are
electrically excitable, release mediators in response to
membrane depolarization, and extend neurite-like pro-
cesses (14). In addition, b-cells express many neuronal
proteins (14,15), such as the neurotransmitter g-aminobutiric
acid (GABA) (16,17) or the synaptic cell-surface molecules
neurexin, neuroligin, and SynCAM (18,19). Among them,
neurexin and neuroligin have been shown to participate in
insulin secretion (18,19).
Nogo-A is a high-molecular-weight membrane protein
mostly expressed in the central nervous system (CNS),
oligodendrocytes, and subsets of neurons (20,21), as well
as other tissues, such as skeletal muscle (22). Nogo-A
restricts neuronal regeneration in injured adult spinal cord
and brain and limits plastic rearrangements and functional
recovery after large CNS lesions, such as after spinal cord
dorsal hemisection (23–25). In the intact CNS, Nogo-A
appears to have a stabilizing and controlling role in axonal
sprouting and cell migration (26–28). Cytoskeletal regu-
lators, such as Rho GTPases or cofilin, mediate the axonal
and neurite growth inhibitory action of Nogo-A (28,29).
Nogo-A and its receptor (NgR) are also found in synapses,
where they may influence their stability and function (30–
32).
Here we show that Nogo-A is expressed in pancreatic
islets. We thus explored its potential role on endocrine
pancreas function using mice lacking the two active Nogo-A
alleles (33,34), which were challenged with different in-
sulin secretagogues. Compared with wild-type animals,
Nogo-A knockout (KO) mice presented increased insulin
secretion, resulting in higher glucose clearance. This en-
hanced insulin release resulted from a higher pancreatic
parasympathetic input on islets and from a higher sensi-
tivity of b-cells to cholinergic and GLP-1 stimulation. We
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obtained similar results, i.e., improved insulin secretion
associated with a higher responsiveness of b-cells, in di-
abetic db/db mice treated for a short period with neutral-
izing antibody against Nogo-A. Together, these observations
reveal that Nogo-A is implicated in pancreatic endocrine
function and thence in the control of glucose homeostasis.
RESEARCH DESIGN AND METHODS
Mice. Nogo-A2/2 KO mice were described previously by one of us (33). In all
experiments, C57BL/6J Nogo-A KO male mice were compared with age-
matched C57BL/6J wild-type males. Genotyping was performed by PCR from
genomic DNA isolated from tail biopsies using M58 (TGCTTTGAATTATTC-
CAAGTAGTCC) and M101 (AGTGAGTACCCAGCTGCAC) primers for wild-
type Nogo-A allele (1.4-kb band), and M58 and M63 (CCTACCCGGTAGAA-
TATCGATAAGC) primers for the Nogo-A–deleted allele (1.2-kb band). Five-
week-old male db/db homozygous mice (C57BL/Ks background; BKS.
Cg-Dock7 m+/+ Leprdb/J strain) were purchased from Charles River Labora-
tories (L’Arbresle, France), for the treatment with neutralizing anti–Nogo-A
11C7 mouse antibody (25). Pdx1-GFP (35) and RIP-DTR (36) mice were
previously described. Animals were maintained in a temperature-controlled
room, on a 12-h light-dark cycle, and fed standard rodent chow ad libitum. The
Direction Générale de la Santé of the Canton de Genève approved the study.
Islet isolation. Mice were killed and their pancreata exposed. After clamping
at the porta hepatis (transverse fissure of the liver), the main pancreatic duct
was cannulated with a 27-gauge butterfly needle and retrogradually injected
with 2 mL of collagenase XI (2 mg/mL in Hanks’ balanced salt solution) (Sigma-
Aldrich). After dissection, the pancreas was digested in 3 mL of collagenase XI
solution for 15 min at 37°C and finally disrupted upon vigorous shaking. Islets
were then purified on a Histopaque 1119 (Sigma-Aldrich) gradient, washed
three times with Hanks’ 13 BSA 0.1%, and finally “fished” (i.e., handpicked)
twice to increase purity.
Fluorescence-activated cell sorter analysis. For fluorescence-activated
cell sorter (FACS) sorting of GFP+ cells, isolated Pdx1-GFP islets were dis-
sociated into a single-cell suspension with trypsin 0.25%. Live b-cells were
isolated as DAPI-GFP+ cells by FACS with MoFlo (Dako-Cytomation).
RT-PCR. Total RNA from the brain (cerebrum), sciatic nerve, pancreas, and
isolated islets of C57BL/6J control mice were extracted with the RNeasy mini
kit (Qiagen) and RNeasy micro kit (Qiagen), respectively. Total RNA from
sorted b-cells was extracted using Trizol. cDNA were prepared using Super-
script II RT kit (Invitrogen), and thereafter PCR was performed with the Red
Taq kit (Sigma-Aldrich). The 59 and 39 primers were chosen from different
exons. The sequences of the primers are available upon request.
Western blotting. Brain, sciatic nerves, pancreas, and isolated islets from
Nogo-A KO and C57BL/6J mice were homogenized using a polytron in lysis
buffer (50mmol/L Tris-HCl, pH 7.5, 250mmol/L NaCl, 1% Triton X-100, 1 mmol/L
EDTA, and 1 mmol/L dithiothreitol) containing complete protease inhibitors
(Roche) and incubated for 30 min on ice. Lysates were sonicated and clarified
by centrifugation. Protein concentrations were then determined. Whole cell ex-
tract samples were fractionated by SDS-PAGE and transferred to Immobilon-P
membranes (Millipore) for immunoblotting with anti–Nogo-A 11C7 (1/10,000;
M.E.S.) and rabbit anti–b-actin antibody (1/5,000). Detection was performed
using peroxidase-conjugated anti-rabbit IgGs (1/5,000; Promega). Bands were
visualized by enhanced chemiluminescence (ECL; Amersham) according to
the manufacturer’s instructions.
Immunofluorescence and immunohistochemistry. Collected pancreata
were weighted and then rinsed in cold PBS and fixed overnight at 4°C in
paraformaldehyde 4%. Tissues were dehydrated, embedded in paraffin, and
sectioned at 5 mm with a microtome. The primary antibodies used for im-
munofluorescence were mouse antiglucagon (1/1,000; Sigma-Aldrich), guinea
pig anti-insulin (1/400; Dako), rabbit anti-PP (1/200; Bachem), rabbit anti-
somatostatin (1/200; Dako), rabbit anti-Pdx1 (1/5,000; gift from Chris Wright,
Vanderbilt University, Nashville, TN), rabbit anti-MafA (1/500; Bethyl Labora-
tory), rabbit anti-Nkx6.1 (1/800; BCBC), rabbit anti–Glut-2 (1/200; gift from
Bernard Thorens, Center for Integrative Genomics, University of Lausanne,
Switzerland), and rabbit anti-PC1/3 (1/200; gift from Ole Madsen, Novo Nor-
disk, Bagsværd, Denmark).
For immunohistochemistry, dewaxed and rehydrated sections were per-
meabilized in 0.1% Triton X-100, washed, and blocked in 3% BSA and 0.1%
Tween in PBS. The primary antibodies were incubated overnight. After washing
in PBS, sections were incubated with specific secondary antibodies coupled to
either Alexa 488 (Molecular Probes) or Cy3 (Jackson ImmunoResearch). Both
islet cell mass and b-cell mass were assessed by measuring the endocrine
synaptophysin-positive area, or the insulin-positive area, on four different
sections, separated by 200 mm each (n = 3), multiplied by the pancreas weight.
Specimens were mounted in polyvinyl alcohol and examined with a Leica
confocal microscope (DM 5500). Tissue surface and cell numbers were mea-
sured with NIH Image J 1.60 or Bitplane Imaris (v7.0) softwares.
In vivo insulin secretion assays. For intraperitoneal glucose tolerance tests
(ipGTTs), overnight-fasted animals (n = 10) received an intraperitoneal glu-
cose injection (2 g/kg) (Sigma-Aldrich), and blood was collected from the tail
vein at 0, 15, 30, 60, 90, and 120 min into centrifuge tubes treated with lithium
heparin. For intravenous GTTs, overnight-fasted animals (n = 7) were anes-
thetized with isoflurane and injected with a solution of glucose alone (1 g/kg)
or supplemented with 0.53 mmol/L carbachol (Sigma-Aldrich) (37) into the
retroorbital capillary plexus. Blood samples were collected from the retro-
orbital plexus at 0, 1, 5, 20, and 50 min into centrifuge tubes treated with
lithium heparin. Blood glucose was assessed with Glucometer Dex2 (Bayer
Corporation). Glycemic area under the curve was measured from time 0 to 120
min, after subtraction of basal glycemia. After immediate centrifugation,
plasma was separated and insulin levels assessed with the Ultrasensitive Rat
Insulin ELISA kit (Mercodia).
Insulin tolerance tests. Animals fasted for 6 h were intraperitoneally injected
with recombinant human insulin (0.5 units/kg, Actrapid; Novo Nordisk), and
blood glucose was measured from the tail vein at 15, 30 45, 60, and 120 min.
Protein extraction and hormone content measurements. Pancreata col-
lected for hormone measurements were homogenized in 5 mL (n = 5–11) acid-
ethanol solution (74% ethanol and 1.4% HCl). Samples were sonicated and
centrifuged. The supernatants were submitted to immunoassay experiments
using either the Glucagon RIA kit (Linco) or Ultrasensitive Rat Insulin ELISA
kit for glucagon and insulin content measurements, respectively.
In vitro insulin secretion assays. Batches of 10 isolated islets from four mice
were preincubated for 30 min in 1 mL Krebs-Ringer bicarbonate HEPES buffer
(KRBH) supplemented with 0.1% BSA and 1.4 mmol/L glucose at 37°C. Next, the
supernatant was replaced by 0.5 mL KRBH supplemented with 0.1% BSA and
1.4, 2.8, 4.2, 8.4, and 16.8 mmol/L glucose was added for another 30 min at 37°C
(n = 3–4). Additionally, islets were incubated for 30 min in 0.5 mL KRBH
containing glucose, 0.1% BSA, and 10 mmol/L carbachol (Sigma-Aldrich) or 100
nmol/L GLP-1 (Bachem) (n = 3–4) (38,39). Secreted and total insulin in the
supernatant was measured in micrograms per liter with the Ultrasensitive Rat
Insulin ELISA kit. Similar insulin contents between islet batches were
assessed after removal of the supernatant and acid-ethanol extraction. Se-
creted insulin was reported as the percentage of secreted insulin normalized
to the total insulin content of 10 islets.
Vagal stimulation of islet hormone secretion. 2-Deoxy-D-glucose (2DG)
(Sigma-Aldrich) was injected intravenously (50 mg/kg) into 2-month-old adult
control and Nogo-A KO mice (n = 5). For PP, mice were fasted overnight and
blood samples were collected at 0, 15, and 30 min (40). For GLP-1 and GIP,
mice were kept with access to food, and blood samples were collected at
0 and 10 min (40). Blood samples were collected from the retrobulbar capil-
lary plexus of anesthetized mice in chilled tubes treated with lithium-heparin.
For plasma GLP-1 and GIP measurements, according to the manufacturer’s
protocol, dipeptidyl peptidase-4 inhibitor (Millipore) was added in tubes and
blood samples were immediately processed. Plasma was assayed for total GIP,
GLP-1, and PP using a MILLIPLEX mouse gut hormone kit (#MGT-78 K; Millipore)
and the Bioplex (Bio-Rad) at the Mouse Metabolic Evaluation Facility (Center for
Integrative Genomics, University of Lausanne, Lausanne, Switzerland).
In vivo administration of neutralizing anti–Nogo-A 11C7 antibody.
Neutralizing anti–Nogo-A 11C7 mouse antibody (Novartis) and nonspecific
anti-BrdU mouse antibody (AbSerotec) were intravenously infused once
a week (2,450 ng/dose), during 2 weeks (4,900 ng in total) through the retro-
orbital capillary plexus in anesthetized mice.
Statistical analysis. All results were reported as mean 6 SEM. Groups were
compared with nonparametric tests (one tailed Mann-Whitney), reported as
P values. All tests were performed using the GraphPad Prism software.
RESULTS
Nogo-A is expressed in endocrine cells of the
pancreas. In the adult mouse pancreas (2-month-old
males), we detected by RT-PCR the expression of Rtn4a
(Nogo-A transcript) in extracts from isolated islets of
Langerhans (Fig. 1A). Rtn4a transcripts were also found in
EGFP+ b-cells isolated by flow cytometry [obtained from
Pdx1-EGFP transgenic mice (35)] (Fig. 1A). Rtn4a ex-
pression in b-cells was confirmed by deep sequence anal-
ysis performed on RNA extracts of b-cell–depleted islets
obtained from RIP-DTR transgenic mice treated with
diphtheria toxin (36) (Supplementary Fig. 1A). Finally, is-
let expression of Nogo-A at the protein level was observed
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by Western blot (Fig. 1B). We observed Rtn4a transcripts
in human and rat islets as well (Supplementary Fig. 1B).
Nogo-A KO mice display increased insulin secretion
and lower glycemia, yet they have a normal b-cell
mass. The pancreatic expression of Nogo-A led us to
wonder whether Nogo-A regulates insulin secretion, like
neuroligin (18). Body weight as well as the pancreas-to-
body weight ratio was unchanged in Nogo-A KO mice
(body weight: wild type 28.47 6 0.86 g, KO 23.82 6 1.89 g;
n = 10, P = NS; pancreas-to-body weight ratio: wild-type
0.99 6 0.05%, KO 0.86 6 0.09%; n = 5, P = NS) (Fig. 2A and
B). We measured plasma values of glucose, insulin, and
glucagon in fasted and random-fed conditions. After 16-h
fasting, plasma glucose, insulin, and glucagon levels were
normal in KO mice (Fig. 2C–E). However, in a random-fed
situation (a period during which insulin secretion is stim-
ulated by glucose, glucoincretins, and neurotransmitters),
KO animals had significantly less blood glucose (wild type
10.66 6 0.35 mmol/L, KO 8.48 6 0.31 mmol/L; n = 5, P =
0.04), associated with increased insulinemia (wild type
0.50 6 0.02 mg/L, KO 1.23 6 0.28 mg/L; n = 6, P = 0.04)
(Fig. 2C and D), but normal glucagonemia (wild type
60.79 6 4.62 pg/L, KO 66.54 6 13.29 pg/L; n = 6, P = NS)
(Fig. 2C–E).
At the histological level, islet number, structure, size,
and shape and b-cell mass were normal in Nogo-A KO
mice (Supplementary Fig. 2A–E and not shown). The total
pancreatic glucagon content was unchanged (wild type
338.07 6 8.92 pg, KO 344.02 6 4.96 pg; n = 9–11, P = NS)
(Supplementary Fig. 2G), and the pancreatic insulin con-
tent was slightly increased (wild type 554.65 6 54.54 ng,
KO 763.51 6 37.67 ng; n = 5, P , 0.05), thus suggesting
that insulin content per b-cell was somewhat augmented
(Supplementary Fig. 2F).
These observations reveal that although Nogo-A KO
mice have a normal b-cell mass, they exhibit lower glycemia
associated with higher insulin secretion in the random-fed
condition, but without overt hypoglycemia.
Cholinergic-dependent glucose-stimulated insulin
secretion is enhanced in Nogo-A KO mice. In order to
study the enhanced insulin secretion, we performed GTTs
in response to different secretagogues (glucose alone or
supplemented with carbachol) and after different routes of
administration (intraperitoneal or intravenous injection).
Besides increased plasma glucose and cholinergic stimu-
lation (carbachol), insulin secretion from b-cells is also
induced in response to the stimulated parasympathetic
nervous system upon intraperitoneal injection of glucose
(41). Overnight-fasted Nogo-A KO animals showed im-
proved glucose clearance after intraperitoneal glucose
administration (2 g/kg), as revealed by a decreased area
under the curve (wild type 709.875 6 72.73 mmol/L/min,
KO 378.95 6 31.17 mmol/L/min; n = 4, P = 0.01) (Fig. 3A).
The stimulated insulin secretion was significantly higher 1
h after glucose injection in Nogo-A KO animals (Fig. 3B).
Since insulin sensitivity was comparable in KO and wild-
type mice (Fig. 3C), the faster glucose clearance in the
former was thus due to a higher insulin secretion. We then
explored the means by which insulin secretion is potenti-
ated in Nogo-A KO mice. Therefore, after overnight fasting,
animals were exposed to an intravenous bolus of either
glucose alone (1 g/kg) (Fig. 3D and E) or glucose supple-
mented with the cholinergic analog carbachol (0.53 mmol/L),
so as to mimic the vagal stimulation (Fig. 3F and G). Al-
though control and KO mice similarly corrected the in-
duced hyperglycemia by secreting comparable amounts of
insulin in response to glucose (Fig. 3D–E), insulin secretion
was higher in the KO group when animals were treated
additionally with carbachol (Fig. 3F and G). Taken together,
these observations suggest that in the absence of Nogo-A
activity, the cholinergic vagal stimulation on b-cells triggers
a stronger release of insulin.
The increased insulin secretion in Nogo-A KO mice is
associated with higher parasympathetic input on islet
cells. We reasoned that the enhanced insulin secretion in
Nogo-A KO mice might rely upon higher islet para-
sympathetic input or increased b-cell responsiveness, or
both. The density of parasympathetic (VAChT+), sympa-
thetic (VMAT2+), and sensory (CGRP+) fibers was normal
in Nogo-A KO pancreas (not shown). We assessed the
vagal stimulation on b-cells through the administration of
2DG (50 mg/kg; intravenously). 2DG is an unmetabolizable
glucose analog that blocks intracellular glucose utilization,
thus inducing neuroglycopenia and subsequently stimu-
lating the vagus nerve, which promotes islet hormone se-
cretion (12,42). We estimated the parasympathetic input
on islets by measuring the fasting plasma PP, whose se-
cretion is strictly controlled by parasympathetic stimulus
(43,44). Whereas plasma PP was identical in the two
groups of mice before 2DG injection, 30 min after 2DG,
this value was almost doubled in Nogo-A KO mice (wild
type 101.08 6 11.45 pg/mL, KO 187.09 6 15.33 pg/mL; n =
4, P , 0.05), suggesting an increased parasympathetic in-
put (Fig. 4A). In parallel, we measured the postprandial
plasma glucoincretins, before and after 2DG injection.
GLP-1 was undetectable, as previously reported (45), yet
we could determine that plasma GIP values were lower in
Nogo-A KO mice, irrespective of 2DG treatment, which
correlates with their lower glycemia (Fig. 2C) (before 2DG:
wild type 58.05 6 4.90 pg/mL, KO 34.86 6 3.03 pg/mL, P ,
0.005; 15 min after 2DG: wild type 51.90 6 4.65 pg/mL, KO
36.55 6 4.19 pg/mL, P , 0.05, n = 5) (Fig. 4B). Combined,
the above observations corroborate that the vagal stimu-
lation of insulin secretion is reinforced by a higher para-
sympathetic tone in Nogo-A KO mice.
Using isolated islets, we assessed the responsiveness of
b-cells to various secretagogues downstream of the para-
sympathetic stimulation. Groups of 10 islets with similar
insulin content from control and Nogo-A KO mice
responded similarly to various concentrations of glucose
FIG. 1. Nogo-A is expressed in endocrine and neuronal compartments of
the pancreas. A: Expression of Nogo-A in the brain (cerebrum, C),
sciatic nerve (SN), pancreas (P), islets (I), and sorted b-cells (b) in
2-month-old controls and Nogo-A KO mice, as assessed by RT-PCR.
b-actin is used as internal control. B: Expression of Nogo-A in the brain
(C), sciatic nerve (SN), pancreas (P), and islets (I) in 2-month-old wild-
type and Nogo-A KO mice, as assessed by Western blotting. b-Actin is
used as internal control.
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(Fig. 4C). Accordingly, the expression of b-cell machinery
genes (Insulin1, Insulin2, Slc2a2, GK, MafA, Nkx6.1,
Pdx1, NeuroD1, Kcnj11, PC1, Gpr35, Htr7, Slc24a, and
Trpm2) was fundamentally not altered, even though one
gene, Trpm2, a regulator of insulin secretion (46), was
upregulated in Nogo-A KO animals (Supplementary Fig. 3).
Islets were then submitted to different glucose concen-
trations, supplemented with carbachol (CC; 100 mmol/L).
In this situation, insulin secretion was increased in Nogo-A
KO islets, as compared with control islets (1.4 mmol/L +
CC: wild type 0.070 6 0.008%, KO 0.195 6 0.025%, P ,
0.005; 8.4 mmol/L + CC: wild type 0.170 6 0.025%, KO
0.2876 0.036%, n = 7–13, P, 0.05) (Fig. 4D). Finally, islets
were incubated with glucose (8.4 mmol/L) supplemented
with GLP-1 (100 nmol/L). Insulin secretion in response to
glucose + GLP-1 was similar between wild-type and KO
islets (Fig. 4E). These observations reveal that isolated
Nogo-A KO islets secrete more insulin specifically in re-
sponse to glucose supplemented with carbachol.
Diabetic db/db mice display improved insulin
secretion after administration of neutralizing anti–
Nogo-A antibody. The constitutive inactivation of Nogo-
A confers to metabolically healthy mice the ability to more
efficiently correct the induced hyperglycemia thanks to an
improved insulin secretion. In order to explore the rele-
vance of these observations to diabetes, we investigated
the capacity of neutralizing anti–Nogo-A monoclonal anti-
body (termed 11C7) to promote insulin secretion in recent-
onset T2D animals. Five-week-old diabetic db/dbmice (i.e.,
lacking the leptin receptor) were treated with either anti–
Nogo-A or control (anti-BrdU) antibody, as previously
described (23). 11C7 was previously reported to inhibit
Nogo-A in the CNS of adult rats, where it enhances the
sprouting and regrowth of injured spinal cord axons (23).
In brief, mice received two intravenous injections of 4.9
mg antibody (245 mg/kg), either 11C7 or control antibody,
during a 2-week period. One week after the second in-
jection, insulinemia in random-fed db/db mice treated
FIG. 2. Nogo-A KO mice have high plasma insulin in the random-fed condition. Body weight (n = 10 mice, P = NS) (A) and the relative pancreatic
weight (n = 5, P = NS) (B) remain unaffected in Nogo-A KO mice. C: Blood glucose is significantly decreased in the random-fed condition in KO
animals, as compared with wild type (n = 5–6, P < 0.05). D: Plasma insulin in the random-fed condition is higher in KO mice (n = 5–6, P < 0.05).
E: Plasma glucagon remains constant in wild-type and KO animals, whether in fasted or random-fed conditions (n = 5–6, P = NS). **P < 0.005.
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FIG. 3. Improved insulin secretion in Nogo-A KO mice in response to simultaneous glucose and nervous stimulation. A: Blood glucose (mmol/L)
after intraperitoneal injection of 2 g/kg glucose is cleared faster in KO mice than in controls (n = 5, *P < 0.05, **P < 0.005). B: Plasma insulin (mg/L)
during ipGTTs is higher (n = 10, *P< 0.05, **P< 0.005). C: Blood glucose after intraperitoneal injection of 0.5 units/kg insulin is similar between wild
type and KO (n = 7–8, P = NS). Blood glucose (D) and plasma insulin (E) after intravenous injection of glucose (1 g/kg). Both wild-type and KO groups
have a broadly similar glucose clearance and insulin level (n = 5–6, P = NS). Blood glucose (F) and plasma insulin (G) after intravenous injection of
glucose (1 g/kg) supplemented with the cholinergic analog carbachol (0.53 mmol/L). Compared with controls, KO mice present an improved glucose
clearance, associated with a more potent insulin secretion (n = 5–6, *P < 0.05, **P < 0.005).
C.B. BONAL AND ASSOCIATES
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with anti–Nogo-A antibody was higher than in control
antibody–treated animals (control 13.94 6 5.02 mg/L, 11C7
32.28 6 8.14 mg/L; n = 3, P , 0.05), yet the total pancreatic
insulin content remained unchanged (not shown). No ef-
fect was detected on glucose levels or body weight, most
probably due to the described severe insulin resistance in
peripheral tissues in db/db mice, and also perhaps to the
shortness of the treatment period. Antibody-treated db/db
mice underwent different metabolic challenges, as follows.
During ipGTTs, db/db mice treated with anti–Nogo-A had
higher plasma insulin (15-min control 1.25 6 0.08 mg/L,
11C7 2.17 6 0.15 mg/L; n = 3–4, P , 0.05) (Fig. 5A). In
another experiment, we assessed the glucose-induced in-
sulin secretion by intravenously providing a bolus of glu-
cose (1 g/kg); in this situation, plasma insulin levels were
similar most of the time in anti-Nogo-A–treated mice, like
in Nogo-A KO mice (Fig. 2E and Fig. 5B). Yet when the
mice were given glucose and carbachol (0.53 mmol/L)
simultaneously, insulin secretion was fourfold higher on
average in anti-Nogo-A–treated db/db animals (control
10.65 6 2.14, 11C7 46.43 6 8.00; n = 3, P , 0.05) (Fig. 5C)
while the total pancreatic insulin content remained steady
(not shown).
We reasoned that the higher insulin secretion observed
in db/db mice treated with anti–Nogo-A neutralizing anti-
body could result from a higher parasympathetic input
and/or from higher b-cell cholinergic sensitivity, as in
Nogo-A KO mice. We therefore indirectly assessed the
parasympathetic tone after 2DG-induced neuroglycopenia
by measuring the plasma levels of PP, as above. In-
terestingly, fasting basal PP levels before 2DG stimulation
are comparable between healthy wild-type animals and
control db/db mice (not shown), yet after 2DG injection,
they become twofold higher in control db/db animals (wild
type 101.08 6 11.45 pg/mL, control db/db 252.78 6 46.56
pg/mL). In anti-Nogo-A–treated db/db mice, 2DG injection
FIG. 4. Nogo-A KO mice have a higher parasympathetic tone, and their b-cells are more sensitive to glucose supplemented with carbachol. A: After
intravenous injection of 50 mg/kg 2DG, which triggers neuroglycopenia and a subsequent parasympathetic stimulation, plasma PP levels (pg/mL) in
overnight-fasted Nogo-A KOmice are higher than in controls (n = 5, *P< 0.05). B: Plasma GIP (pg/mL) in random-fed Nogo-A KOmice is lower than
in controls (n = 5, *P < 0.05, **P < 0.008). C–E: Sensitivity of b-cells from isolated wild-type and Nogo-A KO islets. C: In response to glucose only,
wild-type and Nogo-A KO islets secrete insulin similarly (n = 16 batches of 10 islets from four mice, P = NS). D: In response to glucose supple-
mented with carbachol (CC; 100 mmol/L), Nogo-A KO isolated islets secrete significantly more insulin than wild-type islets (n = 15 batches of 10
islets, four mice, *P < 0.05, **P < 0.005). E: In response to 8.4 mmol/L glucose supplemented with GLP-1 (100 nmol/L), KO isolated islets secrete
similar insulin as wild-type islets (n = 15 batches of 10 islets, three mice, P = NS).
BETTER INSULIN SECRETION BY Nogo-A MODULATION
1448 DIABETES, VOL. 62, MAY 2013 diabetes.diabetesjournals.org
did not alter the fasting basal plasma PP level (n = 5, P =
NS) (Fig. 5D). Similarly, like in Nogo-A KO mice, GIP levels
were not affected by 2DG administration in random-fed
anti-Nogo-A–treated db/db mice (Fig. 5E) (n = 5, P = NS).
Altogether, these results suggest that the antibody-mediated
neutralization of Nogo-A does not affect the vagal and
incretin input on b-cells.
In parallel studies, anti–Nogo-A antibody was given to
healthy control mice (C57BL/6J background). This treat-
ment did not affect plasma levels of glucose or insulin
(Supplementary Fig. 4), thus addressing a safety issue. The
fact that 11C7 treatment has no effect on wild-type mice
may be because they have normal parasympathetic input,
contrary to Nogo-A KO and 11C7-treated db/db mice, which
have a higher parasympathetic tone (Fig. 4A and Fig. 5D).
These observations were completed with the study of
b-cell responsiveness to various secretagogues using iso-
lated db/db islets cultured in the presence of glucose
supplemented with 100 mmol/L carbachol. Like the Nogo-A
KO islets (above, Fig. 4B), islets from anti-Nogo-A–treated
db/db mice displayed higher insulin secretion in the pres-
ence of glucose supplemented with carbachol (n = 7–15,
P , 0.05), yet their sensitivity to glucose supplemented
with GLP-1 was not affected (Fig. 5F).
Combined together, these different observations reveal
that the administration of Nogo-A–neutralizing antibody
enhances insulin secretion in diabetic db/db mice. Con-
trary to Nogo-A KO animals, the parasympathetic input on
islets is not altered in anti-Nogo-A–treated db/db animals.
However, as in Nogo-A KO mice, b-cell sensitivity to
FIG. 5. Insulin secretion is improved in diabetic db/db mice treated with anti–Nogo-A neutralizing antibody (11C7). A–C: Plasma insulin levels (mg/L)
after injection of glucose are higher in mice treated with anti–Nogo-A antibody than in controls. A: Intraperitoneal injection of 2 g/kg glucose
(n = 2–4, *P< 0.05). B: Intravenous injection of glucose (1 g/kg) (n = 3, *P < 0.05). C: Intravenous injection of glucose (1 g/kg) supplemented with
carbachol (CC; 0.53 mmol/L); the potentiation effect on insulin secretion is marked in anti-Nogo-A–treated mice (n = 3, *P < 0.05). D and E:
Intravenous injection of 2DG (50 mg/kg), which triggers the parasympathetic stimulation. D: The plasma PP levels (pg/mL) in anti-Nogo-A–treated
db/db mice fasted overnight are similar to those of controls (n = 5, P = NS). E: The plasma GIP levels (pg/mL) in random-fed, anti-Nogo-A–treated
db/db mice are similar to those of controls (n = 5, P = NS). F: Sensitivity of b-cells from isolated islets of control and 11C7-treated db/db mice in
response to glucose supplemented with CC (10 mmol/L) or GLP-1 (100 nmol/L). Isolated islets from anti-Nogo-A–treated db/db mice secrete more
insulin in response to 4.2 mmol/L + CC and higher glucose concentrations (n = 7–15 batches of 10 islets, four mice, **P < 0.005).
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glucose supplemented with carbachol is increased in db/db
mice after Nogo-A downregulation.
Globally, the observations made with two independent
experimental systems suggest that when Nogo-A activity is
deleted or significantly impaired, the cholinergic vagal
b-cell stimulation triggers a more potent release of insulin.
b-Cell replenishment after near-total b-cell loss is
not improved by downregulation of Nogo-A. Nogo-A
is a negative modulator of regeneration in the CNS (23–
25). We therefore explored if it has a similar function in
regenerating an injured pancreas. We treated Nogo-A KO
mice also bearing the RIP-DTR transgene with diphtheria
toxin to induce the near-complete destruction of b-cells, as
previously described (36). The trends in glycemia in these
mice were followed for up to 3 months, reflecting the lack
of any beneficial effect for the loss of Nogo-A (Supple-
mentary Fig. 5A). Accordingly, the total pancreatic insulin
content and b-cell mass were unaffected by the down-
regulation of Nogo-A, thus revealing that Nogo-A in-
activation does not improve per se the regeneration
capacity of the pancreas after extreme b-cell loss (Sup-
plementary Fig. 5B and C), even though the genetic
background of Nogo-A KO mice may somewhat influence
the extent of recovery, as reported to occur for spinal cord
regeneration (34).
DISCUSSION
We report here that 1) Nogo-A is expressed in islet cells
and that 2) its genetic inactivation results in increased
insulin secretion through vagal stimulation due to a higher
parasympathetic input and a higher responsiveness of
b-cells to carbachol in the absence of Nogo-A. Similarly, 3)
antibody-mediated neutralization of Nogo-A in diabetic
db/db mice increases the vagal-induced insulin secretion,
by increasing the sensitivity of b-cells to cholinergic
stimuli. Finally, 4) contrary to what is observed in cells of
the injured CNS, Nogo-A downregulation does not ame-
liorate the rate of b-cell regeneration in a model of total
b-cell ablation.
The high vagal stimulation of insulin secretion was
previously reported in obese patients (47,48) and in rodent
models of T2D (fa/fa rats, preobese ob/ob mice, high fat–
fed mice, and mice subjected to long-term glucose infusion
or streptozotocin treatment) (49–54). Yet the precise in-
volvement of the parasympathetic and sympathetic tones,
and the sensitivity of b-cells, was not assessed in these
studies. Using the high fat–fed model, Ahrén et al. (50)
showed higher b-cell sensitivity to carbachol-induced in-
sulin secretion in vitro.
b-Cell hypersensitivity in Nogo-A KO mice is inde-
pendent of the glucose-stimulated insulin secretion
pathway. The molecular mode of action of Nogo-A in the
pancreas is an intriguing question and deserves further
study and elucidation. The changes at the parasympathetic-
to-b-cell synapse, possibly via the intracellular mes-
sengers of Nogo (Rho and Ca2+), as well as effects on
pre- or postsynaptic cytoskeleton, are mechanisms that
could be studied in dissociated coculture systems. Per-
haps the signal transduction leading to insulin secretion is
also altered; we found by quantitative PCR and deep se-
quencing on isolated islets that the relative b-cell expres-
sion of muscarinic and nicotinic receptors, which determine
the sensitivity to cholinergic stimulation (55), as well as
that of other cell signaling mediators, was identical in
extracts from wild-type and Nogo-A KO isolated islets
(not shown). Interestingly, the expression of Trpm2, a Ca2+
channel, and serotonin receptor Htr7, well known to po-
tentiate insulin secretion, was upregulated (46,56). We did
not explore the activation of phospholipase C and the
generation of IP3 and diacylglycerol; however, we ob-
served a similar secretory response to glucose or to glu-
cose supplemented with KCl in isolated wild-type and
Nogo-A KO islets (not shown). This suggests that, in the
absence of Nogo-A, the improved insulin secretion in re-
sponse to glucose/carbachol does not rely on the cell
machinery involved in glucose/KCl-induced insulin secre-
tion. Such dissociation in the sensitivity to different sec-
retagogues was previously shown in other mutants, like
those expressing a dominant-negative form of HNF1a
specifically in b-cells (38,50,57).
Differential involvement of the parasympathetic
input. Insulin secretion is enhanced in diabetic db/db
mice when Nogo-A activity is downregulated with anti-
body treatment; even though this effect is not mediated by
a higher parasympathetic input to islets, it is nevertheless
enhanced by it. However, the short exposure to anti–Nogo-A
antibody (only two injections) was sufficient to increase
the sensitivity of b-cells to glucose concentrations .4.2
mmol/L supplemented with carbachol. This observation
alone raises new hopes in the quest for finding new ways
to promote insulin secretion in diabetic patients.
The phenotype of 11C7-treated db/db mice partially
recapitulates that of Nogo-A KO animals. It must be re-
iterated, though, that it is unclear whether intravenous-
injected monoclonal antibodies can cross the blood-brain
barrier (58,59). In particular, it was shown that anti–Nogo-A
antibody does not cross it (60); therefore, this would pre-
vent any effect on the parasympathetic input from the
CNS. However, we cannot completely exclude that a sig-
nificant action of Nogo-A takes place outside the islets.
Further exploration would be needed to fully address this
aspect, such as by generating a b-cell–specific Nogo-A KO
mouse. Yet, since Nogo-A downregulation also results in
improved insulin secretion in vitro, from isolated islets, we
conclude that Nogo-A acts locally (i.e., at the islet level).
Together, these observations are compatible with Nogo-A
action through combined mechanisms (intra- and extra-
islet).
In conclusion, we have reported herein that Nogo-A is
involved in glucose homeostasis. These results suggest
that Nogo-A is a potential new target for antidiabetic
drugs, by promoting insulin secretion in response to cho-
linergic stimuli, such as after food intake, without hypo-
glycemic events. We must recall, in this regard, that
a neutralizing anti-human Nogo-A antibody is currently
being tested in phase I clinical trials on acutely injured
paraplegic patients in centers of the European Network of
Spinal Cord Injury (M.E.S., in collaboration with Novartis).
The inhibition of Nogo-A, for instance, with a weekly in-
jection of antibody may thus represent an avenue for new
antidiabetic treatments, by acting on the stimulatory input
and thereby on insulin secretion from b-cells.
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